louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03425513: Hepatitis B Virus Prevalence and Risk Factors in Belgium
Official title: Hepatitis B Virus Prevalence and Risk Factors in Middle Limburg Belgium: the Importance of Migration.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatitis B
Keywords: Belgium
Prevalence
Risk factor
Ethnicity
Linkage of care
Lead sponsor: Hasselt University
Sponsor class: OTHER
First posted: 2018-02-07
Enrollment: 1131
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients between the age of 18 and 70 who presented at the emergency department of Ziekenhuis Oost-Limburg, a large hospital in Genk, situated in Middle Limburg.

Brief summary: The aim of this study was to evaluate the current prevalence and risk factors of hepatitis B virus (HBV) infection in a multi-ethnic neighbourhood situated in Middle Limburg, Belgium. Additionally, the investigators will determine linkage of care in hepatitis B surface antigen (HBsAg) positive subjects.

Detailed description: Although the HBV prevalence is generally low in Western countries, such as Belgium, pockets of higher HBV prevalence exist in areas with large immigrant populations. Therefore national prevalence figures can underestimate the burden of HBV infection. The prevalence of chronic HBV in the population-based study in 2003 is believed to be an underestimate due to under-representation of the non-Belgian population. Moreover, by this time there are no data regarding the risk factors for HBV infection in the general population of Belgium.

Even in low-prevalence areas such as Belgium, HBV prevention and control is a public health priority, particularly since safe and effective vaccines are available. The aim of this study was to evaluate the current prevalence and risk factors of HBV infection in a multi-ethnic neighbourhood situated in Middle Limburg, Belgium. Additionally, the investigators will determine linkage of care in hepatitis B surface antigen (HBsAg) positive subjects.

Eligibility criteria: Inclusion Criteria:

* Age between 18 and 70
* Males and females

Exclusion Criteria:

/

Primary outcomes:
measure: Seroprevalence of current HBV infection in the Middle Limburg population
timeFrame: 1 day
measure: Seroprevalence of past or current HBV infection in the Middle Limburg population
timeFrame: 1 day
Secondary outcomes:
measure: Assess risk factors for current HBV infection in the Middle Limburg population
timeFrame: 1 day
measure: Assess risk factors for past or current HBV infection in the Middle Limburg population
timeFrame: 1 day
Other outcomes:
Locations:
city: Genk
country: Belgium
facility: Ziekenhuis Oost-Limburg
state: Limburg
Study officials:
affiliation: Hasselt University
name: Geert Robaeys, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02486536: The Best Dosage and Timing of Polyethylene Glycol for Bowel Preparation Before Capsule Endoscopy
Official title: The Best Dosage and Timing of PEG for Bowel Preparation Before Capsule Endoscopy a Prospective, Single-Blind, Randomized, Multi-center Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Small Bowel Disease
Keywords: capsule endoscopy
polyethylene glycol
bowel preparation solutions
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
Collaborators: name: Huashan Hospital
name: Shanghai East Hospital
name: Shanghai Tong Ren Hospital
First posted: 2015-07-01
Enrollment: 410
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The aim of this study is to evaluate the ideal dose of PEG and timing of bowel preparation in patients referred for CE examination.


Eligibility criteria: Inclusion Criteria:

* Patients aged between 18 and 75 years and referred to capsule endoscopy because of suspected small-bowel disease are prospectively eligible for entry into the study.

Exclusion Criteria:

* Age \< 18 or \> 75 years
* Known or suspected GI stricture or fistula
* A history of GI tract resection
* Swallowing disorders
* Intensive therapy with fasting and parenteral nutrition;with a disease that may reduce movement of the GI tract, such as diabetes mellitus
* Medications that could affect gastrointestinal movement within one week
* Implanted with a medical electronic device
* Active inflammatory bowel disease, toxic megacolon, toxic colitis
* Severe pulmonary, cardiac, renal, or hepatic disease
* Uncontrolled hypertension (systolic blood pressure\>170 mm Hg, diastolic blood pressure\>100 mm Hg);
* Disturbance of electrolytes
* Pregnancy or lactation
* Patients inability to provide written voluntary informed consent
* Participation in another clinical study

Primary outcomes:
measure: the quality of visualization of the small bowel
timeFrame: one week after CE procedure
Secondary outcomes:
measure: patient acceptability
timeFrame: day of CE procedure
measure: diagnostic rate
timeFrame: one year
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Huashan Hospital
state: Shanghai
city: Shanghai
country: China
facility: Tongren Hospital Affiliated to Shanghai Jiaotong University, China
state: Shanghai
city: Shanghai
country: China
facility: Department of Gastroenterology, Renji Hospital, Shanghai Institute of Digestive Diseases, Shanghai Jiao Tong University School of Medicine
state: Shanghai
Study officials:
References:
citation: Wu S, Zhong L, Zheng P, Wang YG, Ding WQ, Yu Q, Hui PP, Chen HM, Gao YJ, Ge ZZ. Low-dose and same day use of polyethylene glycol improves image of video capsule endoscopy: A multi-center randomized clinical trial. J Gastroenterol Hepatol. 2020 Apr;35(4):634-640. doi: 10.1111/jgh.14899. Epub 2019 Dec 15.
Clinical trial NCT01761136: The Safety and Immunogenicity of Haemophilus Influenzae Type b Vaccine in Different Injection Site
Official title: Phase 4 Study of Haemophilus Influenzae Type b Vaccine in Different Injection Site
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Healthy
Lead sponsor: Beijing Center for Disease Control and Prevention
Sponsor class: OTHER_GOV
First posted: 2013-01-04
Enrollment: 680
Sex: ALL
Minimum age (years): 2
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The objective of this study was to evaluate the safety and immunogenicity of Haemophilus influenzae type b vaccine in different injection site.

Detailed description: A randomized trial was conducted in 680 healthy infants with Hib vaccine of two brands. The different sub-groups were selected randomly based on the plan to inoculate vaccines in the upper arm deltoid or vastus lateralis muscle. The safety and immunogenicity were assessed after three or two doses.

Eligibility criteria: Inclusion Criteria:

* participants were under 1 years old, and were in good healthy
* participants were full-time pregnancy and birth weight were more than 2.5 kg

Exclusion Criteria:

* current infectious fever or acute disease
* a history of hypersensitivity to study vaccine components especially tetanus toxoid
* a history of allergy, autoimmune, convulsions, seizures heredity disease
* a history of Hib vaccination or Hib disease
* a history of congenital deformity, developmental disorders or serious chronic diseases, muscle injection contradiction, and immunosuppressive agents, hormone or immunoglobulin received.

Primary outcomes:
measure: Incidence rate of adverse events of Haemophilus influenzae type b vaccine in different injection site
timeFrame: one year
Secondary outcomes:
measure: Antibody titre of Haemophilus influenzae type b vaccine in different injection site
timeFrame: one year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Huaxin Hospital
state: Beijing
city: Beijing
country: China
facility: Beijing Chaoyang Women's and Children's Hospital
city: Beijing
country: China
facility: Beijing Dongba Hospital
city: Beijing
country: China
facility: Cuigezhuang community health service centers
city: Beijing
country: China
facility: Xiaohongmen community health service centers
Study officials:
affiliation: Beijing Chaoyang District Center for Disease Control and Prevention
name: Nianmin Shi
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03683836: Minor Troponin Elevations in Patients With Atrial Fibrillation
Official title: Etiology of Minor Troponin Elevations in Patients With Atrial Fibrillation Visiting Emergency Department
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
Myocardial Ischemia
Lead sponsor: University of Turku
Sponsor class: OTHER
First posted: 2018-09-25
Enrollment: 3394
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with atrial fibrillation admitted to Turku University Hospital emergency department

Brief summary: This study aims at identifying the etiology of troponin-T elevations in patients with atrial fibrillation visiting the emergency department.

Detailed description: The aim of this study is to identify the factors associated with minor cardiac troponin-T elevations in patients presenting in emergency department (ED) with atrial fibrillation (AF) diagnosis , and the possible implications it has on the patients prognosis. Data on 3394 patients from the Turku university hospital catchment area with diagnosis of AF on admission to ED and minor troponin-T elevation were analyzed. Patients were classified into three groups according to the troponin-T value: troponin \<15ng/l, 15-50ng/l and 51-100ng/l. Individual patient records were reviewed.

Eligibility criteria: Inclusion Criteria:

* two troponin T tests within 72 hours of ED admission
* Prior diagnosis of AF or AF at admission

Exclusion Criteria:

* Age \< 18 years

Primary outcomes:
measure: All-cause mortality, myocardial infarction, ischemic stroke
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01389336: Add-on Complex Ayurvedic Treatment in Fibromyalgia-Syndrome Compared to Standard Care Alone
Official title: Kontrollierte Klinische Nicht-randomisierte Pilotstudie Zur Komplexen Āyurveda-Therapie Beim Fibromyalgiesyndrom im Vergleich Zur Konventionellen Standardbehandlung
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fibromyalgia Syndrome
Keywords: Fibromyalgia Syndrome
Fibromyalgia
Ayurveda
Traditional Indian Medicine
CAM
Pain
Chronic Widespread Pain
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
Collaborators: name: Dr.Heinz Horst Deichmann Foundation,Essen,Germany
First posted: 2011-07-08
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Men and Women with Fibromyalgia-Syndrome between 18 und 70 years of age

Brief summary: The aim of this study is to evaluate the effectiveness of an additive complex āyurvedic diagnosis and treatment compared to conventional standard care alone in stationary patients with Fibromyalgia Syndrome.


Eligibility criteria: Inclusion Criteria:

* informed consent
* age between 18 and 70 years
* FMS according to current guidelines

Exclusion Criteria:

* change of pharmacological FMS treatment \>= 6 weeks before inclusion
* pregnancy or breat feeding
* acute psychiatric condition
* severe acute somatic disease
* severechronic comorbidity
* obesity WHO \>= II degree
* bloodcoagulation-disease
* intake of opiods
* current treatment with hyperthermia
* simultaneous participant in other trial
* praticipation in other trial during 6 month before inclusion

Primary outcomes:
measure: Fibromyalgia Impact Questionnaire (FIQ)
timeFrame: max. 3 weeks
Secondary outcomes:
measure: Functional Hanover Questionnaire (FFBH)
timeFrame: max. 3 weeks
measure: State Trait Anxiety Inventory (STAI)
timeFrame: max. 3 weeks
measure: Profile of Mood States (POMS)
timeFrame: max. 3 weeks
measure: Short Form 36 Health Survey (SF-36)
timeFrame: max. 3 weeks
measure: VAS for pain
timeFrame: max 3 weeks
measure: Likert-Scales
timeFrame: max 3 weeks
measure: FIQ
timeFrame: 6 month
measure: FFBH, STAI, POMS, SF-36, VAS, Likert-Scales.
timeFrame: 6 month
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Immanuel Hospital Berlin
Study officials:
affiliation: Charité Medical University Berlin Germany
name: Andreas Michalsen, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kessler CS, Ostermann T, Meier L, Stapelfeldt E, Schutte S, Duda J, Michalsen A. Additive Complex Ayurvedic Treatment in Patients with Fibromyalgia Syndrome Compared to Conventional Standard Care Alone: A Nonrandomized Controlled Clinical Pilot Study (KAFA Trial). Evid Based Complement Alternat Med. 2013;2013:751403. doi: 10.1155/2013/751403. Epub 2013 Sep 1.
Clinical trial NCT00926536: Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance
Official title: Impact of C-arm CT in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transhepatic Arterial Chemoembolization (TACE): Optimal Imaging Guidance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Carcinoma, Hepatocellular
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: Siemens Healthcare Diagnostics Inc
First posted: 2009-06-23
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Patients will be enrolled based on presence of HCC and eligibility for TACE. They will be randomized to one of two arms for imaging navigation to the optimal catheter location for chemotherapy injection to treat the first (possibly sole) tumor target. The two arms will be: TACE using C-arm CT supplemented by DSA or DSA only (only DSA images will be used for navigation and tumor vessel tracking). Navigation to subsequent treatment targets in all patients will be done with fluoroscopy, CACT, and DSA, as is standard of care at Stanford University Medical Center, and is not part of the study. Vascular complexity, which affects navigation difficulty and thus the need for imaging, will be assessed separately for use in data analysis by two radiologists on a four-point scale.

Detailed description: We hope to learn more about the utility of C-arm CT in patients undergoing TACE for HCC. Data will be evaluated with regards to:

1. Sensitivity and specificity to diagnose additional tumors and its impact on transplantation criteria.
2. The ability to decrease procedural time by aiding navigation through complex arterial anatomy.
3. Impact on radiation dose. Although the patient would receive the radiation during C-arm CT, overall the number of DSA angiograms and fluroscopy may decrease, potentially negating any effect of the additional dose from C-arm CT

Eligibility criteria: Inclusion Criteria:

Patients must be affected by HCC

Patients must be 18 years old or older

Patients must have received an abdominal CT, PET/CT scan or MRI, completed prior to the TACE procedure.

Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

Subjects under the age of 18

Pregnant women

Primary outcomes:
measure: Dose Area Product (DAP)
timeFrame: Duration of a TACE procedure, an average of 2 hours
measure: Cumulative Dose (CD), a Measure of Radiation Dose
timeFrame: Duration of a TACE procedure, an average of 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Dr. Rebecca Fahrig
role: PRINCIPAL_INVESTIGATOR
affiliation: Stanford University
name: Nishita N. Kothary
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05828836: Allopurinol and Quality of Life in Liver Cirrhosis
Official title: the Impact of Allopurinol of HRQOL in Cirrhotic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Cirrhosis, Liver
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2023-04-25
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study aims to evaluate the impact of allopurinol on patients' related quality of life.

Detailed description: Cirrhosis is the late stage of liver damage and possess two phases:. The shift from compensated to decompensated cirrhosis is characterized by the onset of complications) which are associated with substantial morbidity and negative Impact on quality of life (QOL)Cirrhosis and its complications have a substantial economic, social, and personal impact on affected patients, as well as their families and caregivers

Eligibility criteria: Inclusion Criteria:

cirrhosis adult both sex

Exclusion Criteria:

* renal insufficiency

Primary outcomes:
measure: Chronic liver disease questionnaire
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Faculty of Pharmacy
Study officials:
References:
Clinical trial NCT06227936: Complications of Cholecystostomy in ACC
Official title: Percutaneous Cholecystostomy, Old-fashioned or There is There Still a Role in ACC?
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Cholecystitis
Keywords: Acute Choleystitis
Cholecystostomy
Tokyo Guidelines
Non-Surgical Treatment
Mortality
High-risk patient
Lead sponsor: Hospital del Mar
Sponsor class: OTHER
First posted: 2024-01-29
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients admited with the diagnostic of Acute Cholecystitis from January 2011 to December 2023

Brief summary: Acute cholecystitis (AC) is the second most frequent pathology in Surgical Emergencies; laparoscopic cholecystectomy (LC) is the gold standard treatment, but not all patients are fit for surgery at the diagnostic. Percutaneous Cholecystostomy (PC) is an alternative to LC but has high comorbidity.

This study aims to analyse the complications of PC and review its indications in the literature.

Detailed description: It is a single-centre retrospective study of 2000 acute cholecystitis in adults from January 2011 to december 2023, including demographyc characteristics, comorbidy severity defined as Charlson Comorbidity Index (CCI), ASA Score, Tokyo Guidelines severity classification,the indicatioons for a PC and local complications of PC.

Eligibility criteria: Inclusion Criteria:

* All patients admited in the Hospital del Mar with the diagnostic of an Acute Cholecystitis

Exclusion Criteria:

* Acute cholangitis
* Acute Pancreatitis
* Neoplasia
* Chronic Cholecystitis
* Patients under 18 yearls old
* Pregnancy

Primary outcomes:
measure: Complications
timeFrame: 2011-2023
measure: Mortality
timeFrame: 2011-2023
Secondary outcomes:
measure: Types of cholecystostomy
timeFrame: 2011-2023
measure: Surgical Rescue
timeFrame: 2011-2023
Other outcomes:
Locations:
Study officials:
affiliation: Hospital del Mar
name: Ana María González Castillo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00795236: Melatonin Studies of Totally Blind Children
Official title: Melatonin Studies in Young Blind Children and Adolescents
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Sleep Disorder
Blindness
Keywords: melatonin
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
Collaborators: name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted: 2008-11-21
Enrollment: 13
Sex: ALL
Minimum age (years): 5
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to learn more about abnormal body rhythms in blind boys and girls that keep them from falling asleep at bed-time or cause them difficulty staying alert during the day. The investigators hope to learn if there are any differences between the body rhythms of girls and boys. The investigators also want to investigate whether age or puberty have an effect on body rhythms.

Detailed description: Subjects will be asked to collect saliva samples in their home hourly throughout the daytime, approximately every 2 weeks. Subjects may be monitored for up to a year, after which they will be discontinued from the study. If subjects are found to be naturally entrained to the 24-hour day, they will be monitored longitudinally for changes. Subjects will be discontinued after their monitoring period is over or after an entrained status has been confirmed. While no specific time commitment is required, we hope most subjects will participant for 4 months - 2 years.

Eligibility criteria: Inclusion Criteria:

* Totally blind
* Between 5-8 yrs or 17-20 yrs of age

Exclusion Criteria:

* Pregnancy
* Light perception
* Low melatonin production
* Taking melatonin
* Co-morbid medical disorders (such as seizure disorders)

Primary outcomes:
measure: To Test for a Proportional Gender Difference in Circadian Status (Free-running Versus Entrained) in Blind Children and in Adolescents, a Chi-square Test of Significance Will be Used for Each Age Group.
timeFrame: Approximately 1 year
measure: To Test for a Proportional Difference in Circadian Status (Free-running Versus Entrained) Between Pre and Post- Pubertal Males in Blind Boys and Young Men, a Chi-square Test of Significance Will be Used for Each Age Group.
timeFrame: Approximately 1 year
measure: To Determine the Efficacy of Melatonin Treatment in Entraining Blind Free-running Children and Young Adults, a Binomial Test Will be Used.
timeFrame: Approximately 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: Oregon Health and Science University
state: Oregon
Study officials:
affiliation: Oregon Health and Science University
name: Alfred Lewy, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: